invitria产品代理

产品分类 > 科研试剂 > invitria产品代理

invitria产品代理

无血清培养基和细胞培养基优化的领导者
InVitria 是 Ventria Bioscience Inc. 的一个部门,其成立的目标是为生物技术行业提供创新产品,以改善细胞培养和生物制造。 InVitria 允许客户从基于细胞的过程中消除动物成分。删除这些组件有助于提高一致性、安全性和效率。 InVitria 的产品是在我们位于堪萨斯州章克申城的制造工厂生产的重组蛋白。这些产品在整个生命科学行业有很多用途,包括再生医学、细胞疗法、生物制造、疫苗、诊断和医疗设备。
动物成分,如胎牛血清 (FBS)、人血清和血清衍生蛋白质,如白蛋白、转铁蛋白、胰岛素和生长因子,已成为许多生物过程中的常用成分。然而,在 1990 年代,出于对产品质量、安全和动物管理的担忧,科学家们开始寻找去除血清和其他动物产品的方法。动物产品是不可取的,因为它们有传播传染性病原体的风险,例如朊病毒(疯牛病)和病毒(HIV)。此外,动物成分和血液衍生产品的不确定性导致批次间差异很大。由于这些原因,食品和药物管理局 (FDA)、欧洲药品管理局 (EMA) 和其他监管机构不鼓励使用这些动物成分。
InVitria 已经开发并商业化了多种重组蛋白和细胞培养基补充剂,并利用其专利技术继续开发组件、培养基产品和生长因子。
价格: 0.00

Leaders in   Serum-free Media and Cell Culture Media Optimization

InVitria, a   division of Ventria Bioscience Inc., was founded with the goal of providing   the biotechnology industry with innovative products to improve cell culture   and biomanufacturing. InVitria allows customers to eliminate animal   components from their cell-based processes. Removing these components helps   improve consistency, safety, and efficiency. InVitria’s products are   recombinant proteins that are manufactured in our manufacturing facility in   Junction City, Kansas. These products have many uses across the life science   industry including in regenerative medicine, cellular therapy,   biomanufacturing, vaccines, diagnostics, and medical devices.

   

Animal components such as fetal bovine serum (FBS), human serum, and serum derived proteins like albumin, transferrin, insulin, and growth factors have been popular ingredients in many biological processes.  However, in the 1990s scientists began searching for ways to remove serum and other animal 

products due   to concerns about product quality, safety, and animal stewardship. Animal   products are undesirable because they pose a risk of transmitting infectious   agents such as prions (Mad Cow Disease) and virus (HIV). In addition, animal   components and blood derived products are undefined leading to high   batch-to-batch variation. For these reasons, the Food and Drug Administration   (FDA), European Medicines Agency (EMA), and other regulatory bodies   discourage use of these animal components.

   

InVitria has developed and commercialized several recombinant proteins and cell culture media supplements and continues to develop components, media products, and growth factors leveraging its patented technology.